On May 16, 2012, a Report setting out the follow-up
recommendations of the DIP Working Group (DIP-WG) on the pilot
implementation of the DIP Methodology was released by the PMPRB. In
its report, the DIP-WG recommended that the Board adopt the DIP
Methodology on a permanent basis.
The DIP Methodology was introduced to address situations where
the price of a patented medicine increases in excess of that
allowable under the CPI-Adjustment Methodology due to a reduction
or termination of benefits to customers (i.e., any reduction given
as a promotion or in the form of rebates, discounts, refunds, free
goods, free services, gifts or any other benefits of a like
nature). Under the DIP Methodology, when a Market-Specific Average
Transaction Price of a drug product increases by more than that
allowable under the CPI-Adjustment Methodology and the patentee
provides the required evidence, the price of the drug product may
increase up to the highest Non-Excessive Average Price